Revenio Group Corporation: Change of industry classification benchmark for Revenio Group Corporation
Revenio Group Corporation Stock Exchange Release March 3, 2015 at 16:35
CHANGE OF INDUSTRY CLASSIFICATION BENCHMARK (ICB) FOR REVENIO GROUP CORPORATION Revenio's ICB classification is as of today Health Care. The reason behind the change is Revenio's strategic transformation into Health Technology Corporation. The ICB classification for Revenio Group Corporation will be changed from Industrial Goods & Services (2700) to Health Care (4500). The change will be valid in the Nasdaq Helsinki's INET trading system as from March 4, 2015. New ICB Classification: 4000 Health Care 4500 Health Care "Since the change in our strategy in 2012 we have travelled with determination towards our goal; Revenio will become and in fact it already is a Healt Technology Corporation as well as the global leader in eye pressure screenings. New development projects that we have just published are focusing on significant global national health challenges. The common denominators of which include screening, follow-up and the global need to make cost savings in health care through preventive measures. Our new industry classification reflects both our current operations and strategy and therefore it is very important for us", states Revenio Group's CEO Olli-Pekka Salovaara. For further information concerning this Exchange Notice, please contact Global Corporate Client Group on +358 9 6166 7287. Revenio Group Oyj Olli-Pekka Salovaara CEO For further information, please contact: President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520 olli-pekka.salovaara@revenio.fi http://www.revenio.fi DISTRIBUTION: Nasdaq Helsinki Financial Supervisory Authority (FIN-FSA) Principal media www.revenio.fi The Revenio Group in brief Revenio is a Finnish health tech group whose core business lies in screening. The Revenio Health Tech segment comprises the business operations of Icare Finland Oy and Oscare Medical Oy, which specializes in osteoporosis screening and assessment. In addition, Revenio has identified new growth opportunities relating to health tech in which common denominators are screening, follow-up and the global need to make cost savings in health care through preventive measures. Revenio seeks vigorous growth in health technology, both organically and through acquisitions and mergers. In 2014, the Revenio Group's net sales totaled MEUR 16.0, with its operating margin for continuing operations standing at 27,5%. The Revenio Group Corporation is listed on Nasdaq Helsinki.